Agomab Announces Results of Annual General Meeting

Agomab (Nasdaq: AGMB)/b) reported results of its Annual General Meeting held May 26, 2026.

Rhea-AI Summary

Agomab (Nasdaq: AGMB)/b) reported results of its Annual General Meeting held May 26, 2026. Shareholders approved all agenda items, including the statutory financial statements for the year ended December 31, 2025, discharge of directors and auditor, and the reappointments of and Tim Knotnerus.

AGM documents and detailed voting results are available on Agomab’s investor relations website.

Argus May 27 session

+5.61% close to close Open Argus

Details

News Market Reaction – AGMB

In the May 27 session, AGMB gained 5.61%, reflecting a notable positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock moved +5.6% in the session following this news. A strong positive reaction aligns with the...

Analysis

The stock moved +5.6% in the session following this news. A strong positive reaction aligns with the company’s ongoing de-risking through cash visibility and maturing pipeline, while this AGM news itself mainly formalized previously disclosed items such as the 2025 statutory accounts and director terms. Investors would need to weigh how often governance or reporting milestones have coincided with durable gains versus prior instances where positive patent or clinical updates led to mixed moves.

Key Figures

AGM date: May 26, 2026 Financial year-end: December 31, 2025 Director term: One year +1 more

AGM date

May 26, 2026

Annual General Meeting held in Antwerp

Financial year-end

December 31, 2025

Statutory financial statements approved for this period

Director term

One year

Reappointment term for Ohad Hammer to Board of Directors

Director term

Four years

Reappointment term for Tim Knotnerus to Board of Directors

Historical Context

4 past events · Latest: May 14

4 events

1. May 14

   Conference participation

   24h Move

   -1.3%

   Announced multiple 2026 scientific and investor conference appearances including AGMB-447 poster.

2. Apr 23

   Earnings and outlook

   24h Move

   +3.3%

   Reported 2025 results, strong cash of €116.5M and $208M IPO proceeds funding to 2029.

3. Mar 26

   Patent grant

   24h Move

   -7.7%

   USPTO granted patent for AGMB-447 with composition-of-matter protection into 2041.

4. Feb 9

   IPO closing

   24h Move

   -0.4%

   Closed IPO of 12,500,000 ADSs at $16.00, raising about $200.0M in gross proceeds.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

statutory financial statements, statutory auditor

2 terms

statutory financial statements financial

"Approval of the statutory financial statements for the financial year ended"

Statutory financial statements are the formal, legally required reports a company must prepare and file with regulators that show its financial position, performance and cash flows. Think of them as an official report card prepared according to fixed rules and often reviewed by an independent auditor; they matter to investors because they provide a consistent, comparable and legally verifiable basis for assessing a company’s health, compliance and financial risks.

statutory auditor regulatory

"and the statutory auditor in respect of the performance of their respective duties"

A statutory auditor is an independent, legally required accountant who examines a company’s financial records and issues an official opinion on whether the financial statements give a true and fair view. Investors rely on this check as a trusted third-party stamp—like a certified inspection—because it reduces the chance that errors, omissions or rule-breaking will mislead people making investment decisions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Antwerp, Belgium, May 27, 2026 – Agomab Therapeutics NV (Nasdaq: AGMB) (“Agomab”), a clinical-stage biopharmaceutical company focused on fibro-inflammation, today announced the results of its Annual General Meeting (AGM) held on Tuesday, May 26, 2026.

All items on the agenda were approved, including:

• Approval of the statutory financial statements for the financial year ended December 31, 2025.
• Discharge to the current and former members of the Board of Directors and the statutory auditor in respect of the performance of their respective duties during the financial year ending on December 31, 2025.
• Reappointment of Mr. Ohad Hammer as a member of the Board of Directors for a term of one year.
• Reappointment of Mr. Tim Knotnerus as a member of the Board of Directors for a term of four years.

The voting result and all documents relating to the shareholders’ meeting are available on the Agomab investor relations website at https://ir.agomab.com/governance/shareholder-meetings.

About Agomab
Agomab is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for fibro-inflammatory diseases with high unmet medical need. Agomab’s product candidates are designed to target established potent pathways and utilize organ-restricted approaches, with the aim of increasing efficacy while minimizing safety liabilities. Fostering a culture of excellence, Agomab’s mission is to pioneer therapeutics that aim to resolve fibro-inflammation and restore organ function to enable people with these disorders to live fuller and healthier lives.

Contacts
Investors
Sofie Van Gijsel
VP of Investor Relations
E-mail: sofie.vangijsel@agomab.com
Phone: +1 781 296 1143
        
Media
Gretchen Schweitzer
Trophic Communications
E-mail: agomab@trophic.eu 
Phone: +49 172 861 8540

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Agomab (Nasdaq: AGMB) approve at its 2026 Annual General Meeting?

Agomab shareholders approved all AGM agenda items on May 26, 2026. According to Agomab, this included statutory 2025 financial statements, discharge of directors and auditor, and the reappointment of board members Ohad Hammer and Tim Knotnerus.

Which financial statements did Agomab shareholders approve at the 2026 AGM for AGMB stock?

Shareholders approved Agomab’s statutory financial statements for the year ended December 31, 2025. According to Agomab, this ratifies the reported results for the 2025 financial year and confirms shareholder support for the company’s financial reporting.

Were Agomab’s board members reappointed at the May 26, 2026 AGM for AGMB?

Yes, two Agomab board members were reappointed at the 2026 AGM. According to Agomab, shareholders reappointed Ohad Hammer for one year and Tim Knotnerus for four years, confirming their continued roles on the Board of Directors.

What does the discharge of Agomab’s directors and auditor mean for AGMB investors?

The AGM granted discharge to current and former directors and the statutory auditor for 2025. According to Agomab, this release concerns their duties’ performance during the 2025 financial year, as is standard in Belgian corporate governance practice.

Where can investors find detailed voting results from Agomab’s 2026 AGM for AGMB?

Investors can access detailed 2026 AGM voting results on Agomab’s investor relations website. According to Agomab, all documents related to the shareholders’ meeting are available online under the governance and shareholder meetings section.